Loading... Please wait... Loading... Please wait...
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/29/2024 | Q1 2024 | -$0.35 | $0 | 06/17/2024 | Q4 2023 | -$0.19 | $0 | 09/29/2023 | Q3 2023 | $0.06 | $0 | 06/30/2023 | Q2 2023 | -$0.38 | $0 | 03/31/2023 | Q1 2023 | -$0.32 | $0 | 03/22/2023 | Q4 2022 | -$0.25 | $0 | 09/30/2022 | Q3 2022 | -$0.23 | $0 | 01/19/2023 | Q2 2022 | -$0.30 | $0 | 03/31/2022 | Q1 2022 | -$0.19 | $0 | 04/14/2022 | Q4 2021 | -$0.01 | $0 | 09/30/2021 | Q3 2021 | -$0.08 | $0 | 06/30/2021 | Q2 2021 | -$0.08 | $0 | 03/31/2021 | Q1 2021 | -$0.19 | $0 |
|---|
A. The conference call for NeuroSense Therapeutics Ltd.'s latest earnings report can be listened to online.
A. The conference call transcript for NeuroSense Therapeutics Ltd.'s latest earnings report can be read online.
A. NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) has a recorded net income of $0. NeuroSense Therapeutics Ltd. has generated $-0.83 earnings per share over the last four quarters.
A. NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) has a price-to-earnings ratio of -1.49 and price/earnings-to-growth ratio is -0.1.
